{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:48:01Z","timestamp":1792010881767,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejca.2026.117079","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:32:14Z","timestamp":1790688734000},"page":"117079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"248","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3691-6454","authenticated-orcid":false,"given":"Elena","family":"Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Douglas Laird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1100-3288","authenticated-orcid":false,"given":"Song","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8002-1869","authenticated-orcid":false,"given":"Inge","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatello","family":"Gasparro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8836-2633","authenticated-orcid":false,"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9538-0829","authenticated-orcid":false,"given":"Lajos","family":"Geczi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6999-1901","authenticated-orcid":false,"given":"Deepak","family":"Kilari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryon P.","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia G.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio V.","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijumon","family":"Chelliserry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9474","authenticated-orcid":false,"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-595X","authenticated-orcid":false,"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2026.117079_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1758834011417039","article-title":"The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy","volume":"3","author":"Javle","year":"2011","journal-title":"Ther Adv Med Oncol"},{"issue":"6330","key":"10.1016\/j.ejca.2026.117079_bib2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ejca.2026.117079_bib3","first-page":"597","article-title":"A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer","volume":"55","author":"Lang","year":"2019","journal-title":"Int J Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.117079_bib4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.ejca.2026.117079_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/PO.18.00283","article-title":"Prospective comprehensive genomic profiling of primary and metastatic prostate tumors","author":"Chung","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117079_bib6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117079_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12894-019-0453-9","article-title":"Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Urol"},{"key":"10.1016\/j.ejca.2026.117079_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1159557","article-title":"PARP inhibitors in metastatic prostate cancer","volume":"13","author":"Taylor","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.117079_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejca.2023.02.022","article-title":"Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers","volume":"185","author":"Lozano","year":"2023","journal-title":"European journal cancer"},{"issue":"5","key":"10.1016\/j.ejca.2026.117079_bib10","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2026.117079_bib11","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2026.117079_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"6486","key":"10.1016\/j.ejca.2026.117079_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax6367","article-title":"Structural basis for allosteric PARP-1 retention on DNA breaks","volume":"368","author":"Zandarashvili","year":"2020","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ejca.2026.117079_bib14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/jpet.114.222448","article-title":"Trapping poly(ADP-ribose) polymerase","volume":"353","author":"Shen","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejca.2026.117079_bib15","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO-25-02834","article-title":"Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4","volume":"44","author":"Armstrong","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117079_bib16","unstructured":"European Medicines Agency. TALZENNA\u00ae (talazoparib) Summary of Product Characteristics. July 2025. (https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talzenna-epar-product-information_en.pdf)."},{"key":"10.1016\/j.ejca.2026.117079_bib17","unstructured":"U.S. Food and Drug Administration. TALZENNA\u00ae (talazoparib capsule) prescribing information. June 2025 (https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=20582)."},{"issue":"1","key":"10.1016\/j.ejca.2026.117079_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"issue":"10502","key":"10.1016\/j.ejca.2026.117079_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet"},{"issue":"10398","key":"10.1016\/j.ejca.2026.117079_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"10502","key":"10.1016\/j.ejca.2026.117079_bib21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejca.2026.117079_bib22","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2026.117079_bib23","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","article-title":"Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial","volume":"11","author":"Carreira","year":"2021","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.ejca.2026.117079_bib24","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","article-title":"Elucidating acquired PARP inhibitor resistance in advanced prostate cancer","volume":"42","author":"Seed","year":"2024","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ejca.2026.117079_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the Phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.ejca.2026.117079_bib26","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.117079_bib27","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3390\/cancers13061201","article-title":"Bioinformatic analysis of the nicotinamide binding site in poly(ADP-ribose) polymerase family proteins","volume":"13","author":"Manasaryan","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ejca.2026.117079_bib28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/cancers14010044","article-title":"Preventing and overcoming resistance to PARP inhibitors: a focus on the clinical landscape","volume":"14","author":"Prados-Carvajal","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.ejca.2026.117079_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103684","article-title":"Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing","volume":"9","author":"Triner","year":"2024","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.ejca.2026.117079_bib30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ejca.2026.117079_bib31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2022.09.010","article-title":"Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate cancer after treatment with rucaparib","volume":"83","author":"Loehr","year":"2023","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.ejca.2026.117079_bib32","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1158\/0008-5472.CAN-21-3201","article-title":"PARP inhibitors\u2014trapped in a toxic love affair","volume":"81","author":"Krastev","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2026.117079_bib33","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ejca.2026.117079_bib34","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/cancers15020504","article-title":"Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer","volume":"15","author":"Chhouri","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.117079_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.713530","article-title":"The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer","volume":"11","author":"Pan","year":"2021","journal-title":"Front Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:14:47Z","timestamp":1792008887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":35,"alternative-id":["S0959804926008610"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117079","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117079"}}